|
Loại |
Nguồn |
| 73 |
Tạp chí |
Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159. |
| 81 |
Tạp chí |
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678. |
| 99 |
Tạp chí |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 150 |
Tạp chí |
Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35. |
| 155 |
Tạp chí |
Trissel LA, Martinez JF, Xu QA.
Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium.
Am J Health-Syst Pharm 1995 ; 52: 710-715. |
| 182 |
Tạp chí |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Tạp chí |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 249 |
Tạp chí |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 251 |
Tạp chí |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 301 |
Tạp chí |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 479 |
Tạp chí |
Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966. |
| 496 |
Tạp chí |
Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746. |
| 763 |
Tạp chí |
Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH.
Drug precipitation within IV tubing : A potential hazard of chemotherapy administration.
Cancer Treat Rep 1985 ; 69: 1325-1326. |
| 905 |
Tạp chí |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 921 |
Tạp chí |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 1287 |
Tạp chí |
Lecompte D, Bousselet M, Gayrard D, Poitou P.
Stability study of reconstituted and diluted solutions of calcium folinate.
Pharm Ind 1991 ; 53: 90-94. |
| 1410 |
Tạp chí |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1415 |
Tạp chí |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74. |
| 1423 |
Tạp chí |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1496 |
Tạp chí |
Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428. |
| 1625 |
Tạp chí |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1662 |
Tạp chí |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37. |
| 1754 |
Tạp chí |
Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244. |
| 1914 |
Thông tin của nhà sản xuất |
Pemetrexed (Alimta®) - Summary of Product Characteristics
Eli Lilly 2016 |
| 1925 |
Tạp chí |
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1953 |
Tạp chí |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 1982 |
Tạp chí |
Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837. |
| 2027 |
Tạp chí |
Walker SE, Shirley L, Puodziunas A.
Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers.
Can J Hosp Pharm 2005 ; 58: 212-222. |
| 2130 |
Tạp chí |
Lokiec F, Amirault P, Bonnans H, Gauzan MF, Sauvage N, Santoni J.
Stabilité du mélange 5-fluoro-uracil-acide fonique : influence des concentrations, du contenant et de la forme de l’acide folinique.
Bull Cancer 1999 ; 86, 11: 946-954. |
| 2181 |
Tạp chí |
Milano G, Renée N.
Etude de compatibilité physicochimique 5- fluoro-uracile (nouvelle préparation française) - acide folinique.
Bull Cancer 1995 ; 82: 189-195. |
| 2295 |
Thông tin của nhà sản xuất |
Fosaprepitant (Emend®) - Summary of Product Characteristics
Merck Sharp Dohme 2013 |
| 2340 |
Tạp chí |
Walker S.E, Law S, Puodziunas A.
Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers
Can J Hosp Pharm 2005 ; 58, 4: 212-222. |
| 3474 |
Thông tin của nhà sản xuất |
Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009 |
| 3523 |
Thông tin của nhà sản xuất |
Ceftriaxone (Rocephin®) - Summary of Product Characteristics.
Roche 2018 |
| 3546 |
Thông tin của nhà sản xuất |
Cefamandole Flavelab - Résumé des caractéristiques du produit
Panpharma SA 2007 |
| 3619 |
Thông tin của nhà sản xuất |
Pamidronate (Pamidronate Actavis®) - Summary of Product Characteristics
Wockhardt 2016 |
| 3621 |
Thông tin của nhà sản xuất |
Phosphate dipotassique - Résumé des caractéristiques du produit
Renaudin 2008 |
| 3634 |
Thông tin của nhà sản xuất |
Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit
Accord Healthcare 2011 |
| 3694 |
Tạp chí |
Smith J.A, Morris A, Duafala M.E, Bertino J.R, Markman M, Kleinberg M.
Stability of floxuridine and leucovorin calcium admixtures for intraperitoneal administration.
Am J Hosp Pharm 1989 ; 46: 985-989. |
| 3753 |
Thông tin của nhà sản xuất |
Tedizolid phosphate (Sivextro®) - Summary of Product Characteristics
Cubist Pharmaceuticals 2014 |
| 3838 |
Thông tin của nhà sản xuất |
Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007 |
| 3933 |
Thông tin của nhà sản xuất |
Acide zolédronique - (Acide zoledronique Teva Pharma) - Résumé des caractéristiques du produit
Teva Laboratoire 2015 |
| 4154 |
Thông tin của nhà sản xuất |
Bleomycin sulfate- Summary of Product Characteristics
Accord Health Care 2018 |
| 4720 |
Thông tin của nhà sản xuất |
Nuzyra (omadacycline - Full prescribing infomation. Paratek Pharmaceuticals updated May 2021.
Paratek Pharmaceuticals 2021 |
| 5012 |
Thông tin của nhà sản xuất |
CHLORURE DE MAGNESIUM 10 POUR CENT (1 g/10 ml) LAVOISIER, solution injectable (I.V.) en ampoule - Résumé des caractéristiques du produit.
LABORATOIRES CHAIX ET DU MARAIS 2018 |
| 5053 |
Thông tin của nhà sản xuất |
PHOSPHATE MONOPOTASSIQUE RENAUDIN 136,10 mg/ml, solution pour perfusion - Résumé des caractéristiques du produit.
LABORATOIRE RENAUDIN 2025 |
| 5058 |
Thông tin của nhà sản xuất |
MINOCIN®, Minocycline For Injection - Summary of Product Characteristics.
Melinta Therapeutics, 2025 |
| 5071 |
Thông tin của nhà sản xuất |
FOLINATE DE CALCIUM AGUETTANT 100 mg, poudre pour solution injectable - Résumé des caractéristiques du produit.
LABORATOIRE AGUETTANT 2018 |
